Aegis Therapeutics announced that it has developed a breakthrough technology, Intravail absorption enhancement technology, which would improve the bioavailability of drugs that are delivered through the nose. It has solubility enhancement effects similar to that in solid dosage forms.
The technology being applied to a pill for the first time, the formulation has enhanced the availability of the decongestant phenylephrine by approximately 50 per cent.
The Intravail technology has the alkylsaccaride derived excipients. These excipients in turn have proved to allow small molecules and therapeutic proteins (till 30,000 Daltons) to pass through the mucose membranes of the nose.
The company also claims that the excipient does not allow for irritations that are usually associated with the delivery of proteins in large amounts through sensitive tissues of the nose.
Intravail exipients are soluble in pharmaceutically permitted oils. Hence, its usage is permitted as oral absorption enhancers in gel caps as well, going by Aegis.
